文献速递核素与放射性配体治疗肿瘤 PET/CT

成纤维细胞激活蛋白靶向放射性核素治疗:首批(临床前)临床研究的背景、机遇与挑战

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-02-23

该综述检索PubMed和临床试验注册库,汇总截至2022年7月22日关于FAP靶向放射性核素治疗(FAP TRT)的35篇文献,涉及FAPI-04、FAPI-46、FAP-2286等多种示踪剂。已有超过100例晚期难治性肿瘤患者接受[177Lu]Lu-FAPI-04、[90Y]Y-FAPI-46等治疗,出现客观缓解且不良事件可控,但尚无前瞻性数据,早期结果鼓励进一步研究。

要点

  • FAP在多种癌症间质中高表达,是潜在的诊断与治疗靶点。
  • 已报告超过100例患者接受不同FAP TRT,难治性晚期肿瘤出现客观缓解,不良事件可控。
  • 尚无前瞻性数据,早期结果鼓励进一步研究。

核心结论

  • FAP靶向放射性核素治疗在难治性终末期癌症患者中产生客观缓解,不良事件可控,但尚无前瞻性数据,早期结果鼓励进一步研究。

研究设计与样本

  • 综述:检索PubMed(截至2022年7月22日)及临床试验注册库(2022年7月15日),纳入报告剂量学、治疗反应或不良事件的FAP TRT临床前与临床研究,共识别35篇相关论文。

主要发现

  • 共纳入FAPI-04、FAPI-46、FAP-2286、SA.FAP、ND-bisFAPI、PNT6555、TEFAPI-06/07、FAPI-C12/C16和FSDD等示踪剂进行综述。
  • 已报告超过100例患者接受[177Lu]Lu-FAPI-04、[90Y]Y-FAPI-46、[177Lu]Lu-FAP-2286、[177Lu]Lu-DOTA.SA.FAPI和[177Lu]Lu-DOTAGA.(SA.FAPi)2等不同FAP靶向放射性核素治疗。
  • 在这些研究中,FAP靶向放射性核素治疗在难治性终末期癌症患者中产生客观缓解,不良事件可控。

局限性

  • 尚无前瞻性数据可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fibroblast activation protein (FAP) is highly overexpressed in stromal tissue of various cancers. While FAP has been recognized as a potential diagnostic or therapeutic cancer target for decades, the surge of radiolabeled FAP-targeting molecules has the potential to revolutionize its perspective. It is presently hypothesized that FAP targeted radioligand therapy (TRT) may become a novel treatment for various types of cancer. To date, several preclinical and case series have been reported on FAP TRT using varying compounds and showing effective and tolerant results in advanced cancer patients. Here, we review the current (pre)clinical data on FAP TRT and discuss its perspective towards broader clinical implementation. METHODS: A PubMed search was performed to identify all FAP tracers used for TRT. Both preclinical and clinical studies were included if they reported on dosimetry, treatment response or adverse events. The last search was performed on July 22 2022. In addition, a database search was performed on clinical trial registries (date 15th of July 2022) to search for prospective trials on FAP TRT. RESULTS: In total, 35 papers were identified that were related to FAP TRT. This resulted in the inclusion of the following tracers for review: FAPI-04, FAPI-46, FAP-2286, SA.FAP, ND-bisFAPI, PNT6555, TEFAPI-06/07, FAPI-C12/C16, and FSDD. CONCLUSION: To date, data was reported on more than 100 patients that were treated with different FAP targeted radionuclide therapies such as [177Lu]Lu-FAPI-04, [90Y]Y-FAPI-46, [177Lu]Lu-FAP-2286, [177Lu]Lu-DOTA.SA.FAPI and [177Lu]Lu-DOTAGA.(SA.FAPi)2. In these studies, FAP targeted radionuclide therapy has resulted in objective responses in difficult to treat end stage cancer patients with manageable adverse events. Although no prospective data is yet available, these early data encourages further research.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Privé BM, Boussihmad MA, Timmermans B, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023. PMID: 36813980. doi:10.1007/s00259-023-06144-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。